WallStSmart
AKTX

Akari Therapeutics PLC

NASDAQ: AKTX · HEALTHCARE · BIOTECHNOLOGY

$5.35
+2.10% today

Updated 2026-04-30

Market cap
$6.00M
P/E ratio
0.00
P/S ratio
478,368.50x
EPS (TTM)
$0.00
Dividend yield
52W range
$3 – $59
Volume
0.3M

Akari Therapeutics PLC (AKTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2010201120122013201420152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$0.00$0.00$10159.00$39772.00$0.00$35848.00$19205.00$8907.00$4126.00$3708.00$4000.00$13999.00
Gross profit$0.00$0.00$-10159.00$-39772.00$0.00$-35848.00$-19205.00$-8907.00$-4126.00$-3708.00$-4000.00$-13999.00
Gross margin
R&D$247000.00$841000.00$1.02M$1.28M$6.42M$5.80M$17.31M$23.29M$15.59M$16.65M$12.19M$9.13M$9.56M$8.02M$6.98M$2.81M
SG&A$545000.00$1.41M$734000.00$2.33M$3.76M$5.50M$9.94M$11.67M$10.90M$8.22M$9.16M$8.08M$13.53M$11.36M$9.66M$9.28M
Operating income$-792000.00$-2.25M$-3.67M$-3.61M$-10.18M$-30.58M$-27.25M$-34.96M$-19.99M$-24.87M$-17.98M$-17.21M$-23.09M$-16.81M$-21.64M$-17.27M
Operating margin
EBITDA$-792000.00$-2.12M$-3.36M$-3.42M$-10.19M$-19.28M$-27.25M$-37.18M$-16.43M$-24.73M$-17.97M$-17.21M$-23.08M$-16.80M$-19.53M$-17.35M
EBITDA margin
EBIT$-792000.00$-1.98M$-3.36M$-3.42M$-10.20M$-19.29M$-27.29M$-34.96M$-16.47M$-24.75M$-17.98M$-17.21M$-23.09M$-16.81M$-19.55M
Interest expense$5000.00$0.00$1.04M$202000.00$0.00$3.05M$9.15M$2.40M$82000.00$267000.00$205000.00$210101.00$5.34M$0.00$244000.00$949000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-675000.00$-2.12M$-1.44M$-3.62M$-9.65M$-45.32M$-18.14M$-27.92M$-19.95M$-16.85M$-17.08M$-17.42M$-17.75M$-10.01M$-19.79M$-17.30M
Net income growth (YoY)-213.9%+32.3%-152.3%-166.5%-369.7%+60.0%-53.9%+28.6%+15.6%-1.4%-2.0%-1.9%+43.6%-97.8%+12.6%
Profit margin